Slaninka miceska, Maja
Preferred name
Slaninka miceska, Maja
Official Name
Slaninka miceska, Maja
Main Affiliation
Email
maja.slaninka@medf.ukim.edu.mk
17 results
Now showing 1 - 10 of 17
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Carboxyhemoglobin and Methemoglobin as Markers of Postoperative Pulmonary Complications(Ommega Online Publishers, 2018-05-21); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic significance of serum levels of tumor markers CEA and CA19-9 in patients with colorectal cancer(Македонско лекарско друштво = Macedonian medical association/De Gruyter, 2012); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Serum Matrix Metalloproteinase-2, -7 and -9 (MMP-2, MMP-7, MMP-9) levels as Prognostic Markers in Patients with Colorectal Cancer(University of Sarajevo Faculty of Health Sciences, 2012-12-15); ; ; ; <jats:p>Introduction: Matrix metalloproteinases are produced by tumour cells, hence, they may be associated with tumour progression including invasion, migration, angiogenesis and metastasis. Finding prognostic markers to better identify patients with higher risk for poor survival would be valuable in order to customize pre- and postoperative treatment as well as to enable closer follow-up of these patients. Aim of our study was to examineMMP-2, MMP-7 and MMP-9 serum levels and correlated them with pathological data such as stage of the colorectal cancer (CRC) and outcome.Methods: The investigation included 82 patients with operable CRC without distant metastases, who had underwent blood tests in order to determine the MMP-2, MMP-7 and MMP-9 serum levels in the following time periods: preoperatively, 3, 6, 9 and 12 months postoperatively.Results: The values of the investigated MMPs decrease postoperatively and start to increase 6 month later in patients of all stages of the disease, reaching the highest value 12 month postoperatively with statistically important differences of MMP-2, MMP-7 and MMP-7 serum levels in terms of disease staging and defined points of time. Analysis of the results showed that the MMP-2 serum levels obtained 3 and 12 months postoperatively,than MMP-7 serum levels 12 months postoperatively and the MMP-9 serum levels in all analyzed points in time were in significant association with the CRC patients’outcome.Conclusion: The MMP-2, MMP-7 and especially MMP-9 serum values could be important indicators for diagnosis of the patients with CRC and for monitoring of disease progression.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Улогата на ендоетелин-1 во развојот на дијабетична нефропатија индуцирана со стрептозоцин(Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy, 2006); ; ; ; Dijabeticnata nefropatija pretstavuva edna od hronicnite mikrovaskularni komplikacii na dijabetot, so multifaktorijalna i ne do kraj rasvetlena etiopatogeneza. So ogled na toa sto kaj pacientite so dijabet, osobeno kaj onie so dijabeticna nefropatija, se najdeni zgolemeni vrednosti na endotelin-1, se pretpostavuva deka istiot mozhe da ima znacajna uloga vo razvojot na dijabeticnata nefropatija. Osnovna cel na nashata studija beshe da se detektiraat promenite vo plazmatskoto nivo na endotelin-1 po eksperimentalno induciran dijabet, i dijabeticna nefropatija kaj staorci so streptozocin. So ogled na dobro poznatite efekti na AKE-inhibitorite, vo ovaa studija go ispituvavme i vlijanieto na enalapril (AKE inhibitor) na plazmatskite koncentracii na endotelin-1, kako i negovite efekti vo tretmanot na dijabeticna nefropatija. Ednokratnata i.p. administracija na streptozocin (STZ) predizvika signifikantno zgolemuvawe na plazmatskite koncentracii na endotelin-1, proprateni so jasno izrazeni simptomi i znaci na dijabeticna nefropatija (mikroalbuminurija, zgolemeni urinarni vrednosti na N-acetyl-fl-D-glucosamidase, zgolemeni serumski koncentracii na urea, poliurija). Cetiri nedelniot tretman so enalapril dovede do signifikantno namaluvawe na plazmatskite koncentracii na endotelin-1 i do podobruvawe na simtomite i znacite na dijabeticnata nefropatija. Dobienite rezultati potvrduvaat deka endotelin-1 mozhe da ima znacajna uloga vo razvojot i progresijata na dijabeticnata nefropatija, a AKE inhibitorite, odnosno enalapril, mozhat da ja ublazhat i usporat progresijata na dijabeticnata nefropatija. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, PROJECT MANAGEMENT IN PHARMACEUTICAL INDUSTRY(2023-03-31); ; ; ; Driving a product to the market safely, quickly, and cheaply is the best way for a pharmaceutical company to be successful. In the era of an increased consumer demand for pharmaceutical products, the complex process of new product development has to be shortened as much as possible without damaging the overall quality and efficacy of the new product. The pharmaceutical industry is booming, and the race in delivering new products to the market is speeding up. Pharmaceutical companies encounter enormous challenges during the long and extremely complex product-development process. From the initial research in the early laboratory stages until the ultimate product market launch, this long process includes management in a number of different business processes, such as technical development using quality by design, regulatory strategy, clinical studies, and supply chain. To be able to find the most cost-effective ways of speeding up the process of development of new products, and particularly of the clinical trial phase, pharmaceutical companies faced up the need of introducing and implementing project management, which in other manufacturing industries was done a long time ago. Identification of risks of each of the phases in the process and an effective risk mitigation plan became key factors for success for these companies, both from financial and technical perspective. However, implementation of effective project management in launching new products does not only support the success and profitability of pharmaceutical companies. Effective project management in the pharmaceutical industry also makes available new medical discoveries for patients in need sooner and at lower costs, and by enabling a treatment for a certain disease supports maintenance of human health and improves the quality of life worldwide. The article begins with introduction, continues with the interconnection between the new product development and the need of implementing project management in the pharmaceutical industry, refers to the planning of clinical trials of new products as a very important phase of the business life cycle in this industry, explains the basic definition of project management in the pharmaceutical industry and its specifics, and ends with a conclusion - Some of the metrics are blocked by yourconsent settings
Item type:Publication, STRATEGIC OUTSOURCING IN PHARMACEUTICAL INDUSTRY(2022-02-18); ; ; The pharmaceutical industry is facing a tremendous challenge from the current global economic crisis. Enormous earnings from new “blockbuster” drugs are perishing and old drug targets are leading to limited profits. Despite substantial investment in research and development of new drugs, the return thereof is disappointing. New targets including biologic, biomarker, as well as studies of the genome, as well of drugs for treatment of chronic diseases, have much longer duration of the development phase. Therefore, companies are focused on shortening duration, lowering costs, enhancing efficiency and minimizing usage of resources. All these challenges are forcing the pharmaceutical industry to change its drug development model from a model relying on internal capacities to an open model that embodies aid from a Contract Research Organization (CRO) experienced in understanding regulatory standards, equipped with adequate infrastructure, qualified and competent staff in pharmacy, and experienced in dealing with regional issues. Outsourcing has great importance for pharmaceutical companies. Manufacturers of original pharmaceuticals may opt for outsourcing of different phases of drug development, while generic companies confide the clinical trial – the last phase of drug development – to selected CROs which meet high standards of expertise in performing the studies, using highly reliable analytical methods, located in attractive geographic locations and have competitive pricing. This paper is inspired by the challenges with which the pharmaceutical industry has to cope in the new globalized world. At the beginning the authors provide short introduction to the significance of outsourcing in the case of the pharmaceutical industry; than differentiate Big Pharma from generic pharmaceutical companies; define benefits and risks from outsourcing in the pharmaceutical industry; stress the significance of project management as a key prerequisite of planned and executed outsourced activities; and finally present concluding remarks. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SYMMETRIC DIMETHYL ARGININE AND N-ACETYL-Β-DGLUCOSAMINIDASE LYSOZIMURIA OF PROXIMAL RENAL TUBULES AS A TARGET FOR NEPHROTOXICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE MODIFYING ANTIRHEUMATIC DRUGS(2013); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Expression of matrix metalloproteinases 2, 7 and 9 in patients with colorectal cancer(National Library of Serbia, 2014-01); ; ; ; Matrix metalloproteinases (MMPs) are perceived to play a key role in tumor invasion and metastasis by their capacity to degrade basement membranes and extracellular matrix proteins. The aim of this study was to investigate the expressions of MMP-2, MMP-7 and MMP-9 in tumor tissue and their relation to clinicopathologic features in patients with colorectal cancer. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system(Comenius University, School of Medicine - AEPRESS SRO, 2003); ; ; Jovanoska, EHypertension is associated with impaired endothelial function, which can be explained by a decrease in nitric oxide (NO) generation or by an enhanced inactivation of NO after its release from endothelial cells. The aim of this study was to investigate the effect of long-term treatment with losartan, an angiotensin II (AT1) receptor antagonist, on endothelial dysfunction in an animal model of hypertension in relation to the nitric oxide system. Losartan was administered to 48 sixteen-week-old spontaneously hypertensive rats, in a dose of 10 mg/kg bw/daily in drinking water, for 12 weeks. Systolic blood pressure (SBP) was measured at the beginning, after 4, 8 and 12 weeks of treatment, by the tail-cuff plethysmographic method. At each mentioned time point, a group of 12 animals was sacrificed and blood was withdrawn from the abdominal aorta. Plasma samples were used for determination of total nitrate/nitirite levels, cyclic guanosine monophosphate (cGMP) and endothelin (ET) 1 levels. Statistical evaluation of the results was performed by the use of a computer statistical programme Statistica for Windows 5.0. Losartan produced a significant decrease of SBP at all time points. On the other hand, long-term treatment with this AT1 receptor antagonist produced a significant increase of nitrate/nitrite and cGMP plasma levels. When we compared the values of SBP with plasma nitrate/nitrite as well as with cGMP values, a statistically significant correlation was established. A statistically significant decrease in plasma endothelin 1 values was found during the whole study period. Also, a positive correlation between SBP and plasma endothelin 1 concentrations was observed. Long-term losartan (AT1 receptor antagonist) treatment, apart from its blood pressure lowering effect in hypertension, has beneficial effects on the endothelial dysfunction which is at least partially due to the activation of the nitric oxide system. (Tab. 1, Fig. 2, Ref. 33.) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats(AEPress Bratislava, 2005); ; ; ; Background: The synergistic effects of the combined ACE and NEP inhibition is based both on the blockade of angiotensin II synthesis and degradation of vasoactive peptides and NEP substrates (ANP, arginine, endothelial cells, guanylat cyclase etc.), including bradykinine and the natriuretic peptides, which contribute to vasodilatation, diuresis and improvement of myocardial function. Objectives: This study was undertaken to asses the hypotensive effect of a dual ACE/NEP inhibitor (omapatrilat) in comparison to a NEP inhibitor (candoxatril) and ACE inhibitor (enalapril) in SHRS. Methods: The study was performed in 130 male spontaneously hypertensive rats (SHRS) that were divided into 4 groups and treated orally by a gastric tube for 14 days according to the following dosage regimen: omapatrilat (40 mg/kg b.w./24 h); candoxatril (30 mg/kg b.w./24 h); enalapril (20 mg/kg b.w./ 24 h) and control (water). Systolic blood pressure values were determined at the beginning of the study by the tail-cuff pletysmographic method, at the 7th and 14th day of the treatment, as well as 14 days after the end of the drug administration. For evaluation of the effect of omapatrilat, candoxatril and enalapril on the investigated parameters (plasma atrial natriuretic peptide and serum ACE), 10 ani- mals from the control group were sacrificed at the beginning of the study, and afterwards 10 animals from each group were also sacrificed on the 7th and 14th day of the treatment, as well as 14 days after the end of the drug administration (28th day). Results: The dual ACE/NEP inhibitor, omapatrilat and the ACE inhibitor, enalapril lowered SBP more effectively than the NEP inhibitor, candoxatril at all time points of the experiment (p<0.01). Omapatrilat was slightly more effective than the enalapril treatment. Conclusions: Two-week treatment with the dual ACE/NEP inhibitor omapatrilat caused a significant decrease of the SBP, inhibition of the serum ACE activity and increase of the plasma ANP values, and therefore it should be considered as a new potential therapeutic agent in blood pressure management.